Guggenheim upgraded Johnson & Johnson to Buy from Neutral with a price target of $206, up from $167.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Kenvue Stock (KVUE) Under Watch as Trump Team Eyes Tylenol–Autism Link
- J&J says FDA approves SC induction regimen of Tremfya
- Johnson & Johnson Stock (JNJ) Gains on Early EU Nod for Drug to Treat Muscle-Weakening Disease
- Johnson & Johnson announces positive CHMP opinion of nipocalimab
- JNJ: TECVAYLI/DARZALEX FASPRO regimen shows positive results in study